Latest Oxaliplatin Stories
THOUSAND OAKS, Calif., Jan.
SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
SEATTLE, Nov. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC).
THOUSAND OAKS, Calif., Nov.
NEW YORK, Nov.
DURHAM, N.C., Oct. 26 /PRNewswire/ -- In a review article published this month in The Oncologist, UNC's Dr. Richard M.
THOUSAND OAKS, Calif., Sept.
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients.
LAKE FOREST, Ill., Aug. 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States.